Candel Therapeutics (CADL) Restructuring Costs (2024 - 2025)
Candel Therapeutics (CADL) reported Restructuring Costs of $479000.0 for Q4 2025, down 2.24% on a YoY basis from $490000.0 in Q4 2024, and up 8.13% sequentially from $443000.0 in Q3 2025.
Candel Therapeutics (CADL) Restructuring Costs (2024 - 2025) Analysis & Trends
Candel Therapeutics (CADL) has 2 years of Restructuring Costs data on file, last reported at $479000.0 in Q4 2025.
- For the quarter ending Q4 2025, Restructuring Costs fell 2.24% year-over-year to $479000.0; the trailing twelve-month figure through Dec 2025 stood at $1.8 million (down 5.86% YoY), and the FY2025 full-year result was $1.8 million, down 5.86% from the prior year.
- Restructuring Costs climbed to $479000.0 in Q4 2025, from $443000.0 in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $517000.0 in Q2 2024 to a low of $443000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Candel Therapeutics | 504.70 Mn | 504.70 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 479,000.00 |
| Sep 30, 2025 | 443,000.00 |
| Jun 30, 2025 | 462,000.00 |
| Mar 31, 2025 | 464,000.00 |
| Dec 31, 2024 | 490,000.00 |
| Sep 30, 2024 | 463,000.00 |
| Jun 30, 2024 | 517,000.00 |
| Mar 31, 2024 | 493,000.00 |